Healthcare / BiotechnologyKOSDAQ
$5270.00
+200.00 (+3.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-547.6M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$71.1B
P/E
36.1x
↑EV/EBITDA
19.4x
↑ROE
6.9%
↑Gross Margin
33.6%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+27.3%
FCF CAGR
—
FCF margin
-4.1%
FCF / Net income
-0.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.42B · net income $2.05B · FCF $-547.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $13.42B | $13.42B | $14.67B | $7.32B | $6.50B |
| Net Income | $2.05B | $2.05B | $943.7M | $-4.49B | $-4.49B |
| EBITDA | $3.68B | $3.68B | $2.79B | $-2.62B | $-2.70B |
| EPS | 146.00 | 146.00 | 82.00 | -420.00 | -421.00 |
| Gross Margin | 33.6% | 33.6% | 35.1% | 13.5% | 10.2% |
| Operating Margin | 11.2% | 11.2% | 7.0% | -57.8% | -70.6% |
| Net Margin | 15.3% | 15.3% | 6.4% | -61.4% | -69.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.16 | 0.00 |
| Current Ratio | 8.67 | 8.67 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-547.6M | $-547.6M | $2.61B | $-3.94B | $-4.24B |
| Returns | |||||
| ROE | 6.9% | 6.9% | 3.8% | -35.7% | -26.1% |
| Valuation | |||||
| P/E | 36.10 | 36.10 | 69.76 | — | — |
| EV/EBITDA | 19.36 | 19.36 | 23.34 | — | — |
| P/B | 2.47 | 2.47 | 2.64 | 5.74 | 4.11 |
| Growth & Yield | |||||
| Revenue Growth | -8.6% | -8.6% | 100.6% | 12.5% | — |
| EPS Growth | 78.0% | 78.0% | 119.5% | 0.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
47.4%
EPS terminal req.
$467.62
Spread vs growth
30.6%
5Y implied EPS CAGR
31.1%
EPS terminal req.
$565.83
Spread vs growth
46.9%
10Y implied EPS CAGR
20.1%
EPS terminal req.
$911.27
Spread vs growth
58.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.7%
Start / end P/E
70.4x → 36.1x
EPS bridge
82.00 → 146.00
Residual
-38.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.